Disparities in Cancer Care

Global Oncology

Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

Oncology Business Management

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

CAR T-cell Therapy

COVID-19

Colorectal Cancer

Gastrointestinal Cancer

Urothelial Cancer

Prostate Cancer

Genitourinary Cancers

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Nursing News

Pediatric Oncology

Sarcomas/TGCT

Supportive Care

Shridar Ganesan, MD, PhD, discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice.

Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care

M. Hamza Habib, MD, JD, MBA, FACP, FAAHPM, FRCPI, MRCP, discusses the development of novel technology-based strategies to improve palliative cancer for patients with cancer. 

Dr Habib on Developments in Palliative Care For Patients With Cancer

Patrick Boland, MD, discusses the development of therapeutic strategies targeting KRAS G12C mutations in colorectal cancer.
 

Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC

Haejin In, MD, MPH, MBA, FACS, FSSO, discusses the increased incidence of gastric cancer in minority patient populations, highlighting the disparities that lead to these patient outcomes in the United States.

Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements And Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Print Subscription

eNewsletter

joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

, and now serves as the main digital news writer for 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

The triplet combination of sintilimab, chidamide, and bevacizumab resulted in a high 18-week progression-free survival rate with a favorable toxicity profile in patients with microsatellite stable or mismatch repair–proficient metastatic colorectal cancer, according to data from the phase 2 CAPability-01 trial.

Sintilimab Triplet Demonstrates Efficacy With Acceptable Safety in pMMR/MSS CRC

Lyudmila A. Bazhenova, MD, expanded on key considerations when navigating the use of perioperative immunotherapy for patients with or without oncogenically-driven lung cancers, the importance of multidisciplinary collaboration when deciding on a treatment plan, and the need for increased and earlier implementation of biomarker testing in all patients with lung cancer. 

Multidisciplinary Collaboration and Molecular Testing Are Integral to Treatment Decision-Making in NSCLC

Pembrolizumab continued to demonstrate at trend toward improved overall survival compared with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer. 

First-Line Pembrolizumab Demonstrates Durable Clinical Benefit in MSI-H/dMMR mCRC

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: 

The FDA has granted fast track designation to zotatifin for use in combination with fulvestrant and abemaciclib as second- or third-line therapy for the treatment of patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with disease progression following treatment with endocrine therapy and a CDK4/6 inhibitor.

FDA Grants Fast Track Designation to Zotatifin Plus Fulvestrant/Abemaciclib in ER+/HER2– Breast Cancer

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

2024 nominations are open for Giants of Cancer Care® 

In-person and virtual events just for HCPs

REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Share your views with OncChats 

Specialty

Sound Bites

Why Are You Choosing a Certain Testing Platform in Biomarker Testing?

Tissue and Plasma-Based Mechanisms of Resistance to First-Line Osimertinib in EGFR-Mutant NSCLC: A Multi-Institutional Cohort

Predictive Biomarkers for Treatment With Amivantamab Plus Lazertinib Among EGFR-Mutated NSCLC in the Post-Osimertinib Setting: Analysis of Tissue IHC and ctDNA NGS 

Real-World Testing and Treatment Patterns Among Patients With Stage IV NSCLC: A Retrospective Observational Study

Contemporary Biomarker Testing Rates in Both Early and Advanced NSCLC: Results From the MYLUNG Pragmatic Study

What is NGS Testing?

What is DNA and RNA Testing in Biomarker Testing?

How Do You Explain Adjuvant Therapy in NSCLC?

When Should Patients With NSCLC be Referred to Thoracic Surgeons in Specialized Centers of Care?

NSCLC

Expert Sound Bites

Why Are You Choosing a Certain Testing Platform in Biomarker Testing?

Expert Sound Bites

Tissue and Plasma-Based Mechanisms of Resistance to First-Line Osimertinib in EGFR-Mutant NSCLC: A Multi-Institutional Cohort

Predictive Biomarkers for Treatment With Amivantamab Plus Lazertinib Among EGFR-Mutated NSCLC in the Post-Osimertinib Setting: Analysis of Tissue IHC and ctDNA NGS

Real-World Testing and Treatment Patterns Among Patients With Stage IV NSCLC: A Retrospective Observational Study

Contemporary Biomarker Testing Rates in Both Early and Advanced NSCLC: Results From the MYLUNG Pragmatic Study

What is NGS Testing?

What is DNA and RNA Testing in Biomarker Testing?

Why Are You Choosing a Certain Testing Platform in Biomarker Testing?

How Do You Explain Adjuvant Therapy in NSCLC?

When Should Patients With NSCLC be Referred to Thoracic Surgeons in Specialized Centers of Care?

What are the Benefits and Side Effects of TKIs?

What is a Biomarker in the Context of Tumors?

What is a Gene Mutation and a Gene Fusion?

What is a Chromosomal Rearrangement?

How Do You Explain Neoadjuvant Therapy in NSCLC?

What are Challenges Around Access to Testing?

What are the Benefits and Side Effects of Immunotherapy?